PomDoctor Ltd Reports Strong Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 05 Dec 25
Source: Business Insider
PomDoctor Ltd's stock surged by 10.96%, breaking above its 5-day SMA, following impressive revenue growth figures.
The company reported a 16.2% increase in net revenue for the first half of fiscal 2025, reaching RMB 174,469,851. This growth was largely driven by an 83.2% surge in its online pharmacy segment, showcasing effective promotional strategies.
The successful IPO in October 2025 has provided additional capital for future growth, enhancing PomDoctor's strategic execution capabilities and positioning it well in a competitive market.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
